Please login to the form below

Not currently logged in
Email:
Password:

cenegermin

This page shows the latest cenegermin news and features for those working in and with pharma, biotech and healthcare.

European Commission approves Dompé’s orphan drug

European Commission approves Dompé’s orphan drug

Oxervate will treat patients with neurotrophic keratitis. Italian biopharmaceutical company Dompé has received the go-ahead for Oxervate (cenegermin) for the treatment of moderate-to-severe neurotrophic keratitis (NK), a rare ... Researchers found that

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...

Infographics